Claims
- 1. A compound having the structural formula (I)
- 2. The compound of claim 1, having the structural formula (II)
- 3. The compound of claim 2, wherein R6 is hydrogen.
- 4. The compound of claim 2, wherein R6 is lower alkyl.
- 5. The compound of claim 4, wherein R6 is methyl.
- 6. A compound having the structural formula (III)
- 7. The compound of claim 6, having the structural formula (IV)
- 8. The compound of claim 7, wherein R3 is hydrogen or methyl, and R19 is hydroxymethyl.
- 9. The compound of claim 8, wherein R3 is hydrogen.
- 10. The compound of claim 8, wherein R3 is methyl.
- 11. The compound of claim 7, wherein R3 is hydrogen or methyl, and R19 is hydroxyl.
- 12. The compound of claim 11, wherein R3 is hydrogen.
- 13. The compound of claim 11, wherein R3 is methyl.
- 14. A compound having the structural formula (V)
- 15. The compound of claim 14, having the structural formula (VI)
- 16. The compound of claim 15, wherein R3 is hydrogen or methyl, R6Mod is hydrogen or lower alkyl, R8b is oxo, and R19 is hydroxyl, hydroxymethyl, —O-acetyl, or —O-tetrahydropyranyl.
- 17. The compound of claim 16, wherein R3 is methyl.
- 18. The compound of claim 17, wherein R6Mod is isopropyl.
- 19. A compound having the structural formula (XXVII)
- 20. A compound having the structural formula (XXVIII)
- 21. A compound having the structural formula (VII)
- 22. A compound having the structural formula (XVI)
- 23. The compound of claim 22, having the structural formula (XVII)
- 24. The compound of claim 21, wherein R3 is lower alkyl.
- 25. The compound of claim 22, wherein R3 is methyl.
- 26. A method for synthesizing 21-hydroxy-19-norpregna-4-en-one and substituted analogs thereof, comprising treating a starting material having the structural formula (I)
- 27. A method for synthesizing 21-hydroxy-19-norpregna-4-en-3-one, comprising treating (IX)
- 28. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene, comprising contacting a 19-norpregna-4-en-3-one with gaseous oxygen in the presence of base, followed by reaction of the intermediate so provided with an alkyl halide.
- 29. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene having the structural formula (VIa)
- 30. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)
- 31. The method of claim 30, further including (g) treating the product of step (f) with an acid to produce an acid addition salt.
- 32. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)
- 33. The method of claim 32, further including (i) treating the product of step (h) with an acid to produce an acid addition salt.
- 34. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)
- 35. The method of claim 34, further including (g) treating the product of step (f) with an acid to produce an acid addition salt.
- 36. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 20, in combination with a pharmaceutically acceptable carrier.
- 37. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 21, in combination with a pharmaceutically acceptable carrier.
- 38. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula
- 39. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula
- 40. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 20.
- 41. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 21.
- 42. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula
- 43. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula
- 44. A method for stereoselectively adding an alkyl moiety to the 7α position of a 6 keto steroid comprising providing a C19 or C20 tetrehydropyranyl protected hydroxyl moiety on the steroid and reacting the protected steroid with an alkylhalide in the presence of base.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to provisional U.S. patent application Ser. No. 60/181,738, filed Feb. 11, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60181738 |
Feb 2000 |
US |